ARCH – Age-Related changes in Hematopoiesis
June 14th, 2022 - 9.50-16.30 (CET)
Dipartimento di Biotecnologie e Bioscienze BtBs
June 14th, 2022 - 9.50-16.30 (CET)
Epilessia, difetti della vista, deficit cognitivi e difficoltà motorie. Sono le manifestazioni di una malattia genetica poco conosciuta, la “sindrome da carenza di SOX2” , che sarà al centro di uno studio della professoressa Silvia Kirsten Nicolis del dipartimento di Biotecnologie e bioscienze dell’Università di Milano-Bicocca. Il progetto di ricerca, uno dei 24 selezionati su oltre 200 candidature, si è aggiudicato un finanziamento di 240mila euro da parte dell’alleanza Fondazione Telethon-Fondazione Cariplo.
fonte: pagina web Progetti di ricerca d’Ateneo
MULTIvalent and MULTIfunctional MODulators of Enzyme activity: towards multi-target drugs (Multi-Mode)
Anno: 2022
Bando: FAQC 2022 - prima finestra
Responsabili: LA FERLA BARBARA
Role of AMPK in atrIaL agE-dependent arrhythmogeneSis predisposiTiOn: insigths from humaN and mousE models (MILESTONE)
Anno: 2022
Bando: FAQC 2022 - prima finestra
Responsabili: ROCCHETTI MARCELLA
Advanced Nanotechnology to Assist Keeping the tumor microenvironment Involved in cancer Neutralization (ANAKIN) - I annualità
Anno: 2021
Bando: Investigator Grant - IG 2021
Responsabili: COLOMBO MIRIAM
AGRO2CIRCULAR - Territorial Circular Systemic Solution for the upcycling of residues from the agrifood sector
Anno: 2021
Bando: Demonstration of systemic solutions for the territorial deployment of the circular economy
Responsabili: BRANDUARDI PAOLA
Biodiversità Funzionale Del Vivaio Bicocca
Anno: 2021
Responsabili: LABRA MASSIMO
Brain gene regulation in 3D: long-range promoter-enhancer functional interaction networks in mouse and human brain cells, and their relevance for neurodevelopmental disease
Anno: 2021
Bando: FAQC 2021 - prima finestra
Responsabili: NICOLIS SILVIA KIRSTEN
Deciphering the heterogeneity of dendritic cells in human non-small cell lung cancer - III annualità
Anno: 2021
Bando: AIRC Investigator Grant (IG) 2019
Responsabili: GRANUCCI FRANCESCA
Exploiting DNA damage response protein O-glycosylation to enhance chemotherapy in pancreatic cancer
Anno: 2021
Bando: FAQC 2021 - prima finestra
Responsabili: CHIARADONNA FERDINANDO
Human Neuroimmunobiology
Anno: 2021
Responsabili: GRANUCCI FRANCESCA , KRENN VERONICA
NUOVI FARMACI PER COVID-19: PIATTAFORME PER LO SCREENING "HIGH-THROUGHPUT" DI COMPOSTI
Anno: 2021
Bando: FAQC 2021 - terza finestra
Responsabili: LODOLA FRANCESCO
Search for plastic-degrading enzymes in plastisphere microbial communities from the Gulf on Naples (PLAZY)
Anno: 2021
Bando: FAQC 2021 - terza finestra
Responsabili: LOTTI MARINA
Seguridad Alimentaria Sostenible en el Occidente de El Salvador: agroecología, empoderamiento, participación e innovación
Anno: 2021
Responsabili: BRUNI ILARIA
Supramolecular assemblies in cell invasion as targets for cancer therapy
Anno: 2021
Bando: FAQC 2021 - terza finestra
Responsabili: BROCCA STEFANIA
Targeting DNA double-strand break repair in cancer: genetic and biochemical approaches to study DNA end resection - V annualità
Anno: 2021
Bando: 2017-005 - Call for Proposals 2017 Investigator Grant (IG)
Responsabili: LONGHESE MARIA PIA
Understanding dyserythropoiesis to identify new therapeutic mechanisms in hereditary anemias
Anno: 2021
Bando: Decreto Direttoriale n.1628 del 16-10-2020 - Bando PRIN 2020
Responsabili: RONCHI ANTONELLA ELLENA
Preclinical evaluation of a PGM3 inhibitor as innovative therapeutic approach for pancreatic ductal adenocarcinoma – Terza annualità
Anno: 2021
Responsabili: CHIARADONNA FERDINANDO
lab 2011, building U3, tel. +39 02 6448 3395
see also: PubMed, ResearchGate, GoogleScholar, Scopus, Linkedin
My research activity is devoted to the world of nanobiotechnology: this includes several multidisciplinary activities like the development of nanodrug delivery systems, the study of novel nano-based contrast agents, the formulation design as well as the investigation of interaction between nanomaterials and biological systems.
I am part of a multidisciplinary research group named NanoBioLab.
https://nanobiolab.it/ ; https://www.instagram.com/nanobiolab/
Nanodelivery of biological drugs
Biological drugs include a wide range of active ingredients such as peptides, proteins, genetic materials, whose application is strongly impaired by their poor stability, low permeability and rapid body clearance. The use of nano-based drug delivery systems may overcome these drawbacks and open up new possibility for treatment of several disorders (e.g., cancer, infections, metabolic disorders).
Nanomaterials for diagnostic purposes
The early diagnosis is the key for successfully treating several disorders including cancer. One major need in the field of medical imaging is to increase the specificity and the sensitivity of contrast agents. In this scenario, engineered nanomaterials can be developed for directing contrast agents in specific regions and improve the detection of malignant masses.
Study of Nano-Bio Interactions
Several scientists have pointed out that lack of knowledge in the interaction of nanomaterials with biological systems can seriously limit nanotechnology potential. Thus, part of my research activity aims to give a contribution to this field by investigating nanoparticles intracellular trafficking, their capability of crossing the biological barriers, nanotoxicology or their potential antimicrobic effect.
Development of solid and semisolid formulations
The majority of the new products based on nanomaterials are administered by parenteral injection. However, the use of alternative administration routes may open up new possibilities and better meet the need of the patients in terms of compliance. Thus, part of my research activity is focused on the study of formulation of drug and nanodelivery systems in semisolid and solid dosage forms for pharmaceutical and cosmetic purposes.
Saporin Toxin Delivered by Engineered Colloidal Nanoparticles Is Strongly Effective against Cancer Cells
L. Salvioni, F Testa, L. Barbieri, M. Giustra, J. A. Bertolini, G. Tomaino, P. Tortora, D. Prosperi, M. Colombo
Pharmaceutics. 2022, 14 (7), 1517. https://doi.org/10.3390/pharmaceutics14071517
Development of an effective tumor-targeted contrast agent for Magnetic Resonance Imaging based on Mn/H-Ferritin nanocomplexes
C. Tullio†, L. Salvioni†, M. Bellini, A. Degrassi, L. Fiandra, S Garbujo, R. Rotem, F. Testa, D. Prosperi, M. Colombo
ACS applied biomaterials and interface. 2021, 4(11), 7800–7810. https://doi.org/10.1021/acsabm.1c00724
Impact of Tuning the Surface Charge Distribution on Colloidal Iron Oxide Nanoparticle Toxicity Investigated in Caenorhabditis elegans
L. Amigoni†, L. Salvioni†, B. Sciandrone, M. Giustra, C. Pacini, P. Tortora, D. Prosperi, M. Colombo, M.E. Regonesi. Nanomaterials. 2021, 11(6), 1551. https://doi.org/10.3390/nano11061551
The emerging role of nanotechnology in skincare
L. Salvioni, L. Morelli, E. Ochoa, M. Labra, L. Fiandra, L. Palugan, D. Prosperi, M. Colombo
Advances in Colloid and Interface Science. 2021, 293. https://doi.org/10.1016/j.cis.2021.102437
Nanoparticle-Mediated Suicide Gene Therapy for Triple Negative Breast Cancer Treatment
L. Salvioni, S. Zuppone, F. Andreata, M. Monieri, S. Mazzucchelli, C. Di Carlo, L. Morelli, C. Cordiglieri, L. Donnici, R. De Francesco, F. Corsi, D. Prosperi, R. Vago, M. Colombo
Advanced Therapeutics. 2020, 3(8). https://doi.org/10.1002/adtp.202000007
Thirty Years of Cancer Nanomedicine: Success, Frustration, and Hope
L. Salvioni†, M.A. Rizzuto†, J.A. Bertolini, L. Pandolfi, M. Colombo, D. Prosperi.
Cancers (Basel). 2019, 11(12). https://doi.org/10.3390/cancers11121855
Negatively charged silver nanoparticles with potent antibacterial activity and reduced toxicity for pharmaceutical preparations
L. Salvioni, E. Galbiati, V. Collico, G. Alessio, S. Avvakumova, F. Corsi, P. Tortora, D. Prosperi, M. Colombo.
International Journal of Nanomedicine. 2017, 12, 2517–2530. https://doi.org/10.2147/IJN.S127799
Oral delivery of insulin via polyethylene imine-based nanoparticles for colonic release allows glycemic control in diabetic rats
L. Salvioni, L. Fiandra, M.D. Del Curto, S. Mazzucchelli, R. Allevi, M. Truffi, L. Sorrentino, B. Santini, M. Cerea, L. Palugan, F. Corsi, M. Colombo.
Pharmacological Research. 2016, 110, 122–130, https://doi.org/10.1016/j.phrs.2016.05.016
† equally contributed
Salvioni’s Lab – #SalvioniLab_BtBs
last update: December 2022
Study of bio-active compounds with related bio-organic problems and mechanistic studies of organic reactions are performed through computational approaches.
Prof. Pedro Merino – Instituto de Síntesis Quimica y Catalisis Homogenea, Universidad de Zaragoza, Spagna
Prof. Maria Assunta Chiacchio – Dipartimento di Scienze del Farmaco e della Salute, Università di Catania
Prof. Giuseppe Trusso Sfrazzetto, Dipartimento di Scienze del Farmaco e della Salute, Università di Catania
Legnani’s Lab – #LegnaniLab_BtBs
last update: June 2022